Vilacto Bio Inc. in final stage of developing Anti-Aging Products

COPENHAGEN, Denmark, Nov. 10, 2017 -- Vilacto Bio Inc. (OTC QB:VIBI), announces that it is in the final stage of developing its new anti-aging skin care line.

The company is extremely hopeful with the results observed so far with its new product line, and is anxious to launch pending the final quality tests. As the demand for innovative anti-aging cosmetic products is rising every day, the company believes that people dealing with skin aging stand to benefit from the new products based on the company’s Lactoactive molecule.                           

“Vilacto Bio always aims to deliver preeminent products to benefit our prospective customers. It is very important that our new anti-aging cosmetic line have the best ingredients available from anti-aging specialists.  That is what consumers demand and deserve," states Gert Anderson, CEO of Vilacto Bio Inc.

About Vilacto Bio Inc.:                                                                                                                              

Vilacto Bio Inc. (OTC QB:VIBI), is a biotech company that has developed the now fully patented Lactoactive^® (Lactoactive molecule) that in numerous studies has demonstrated above average effect treating conditions such as inflammatory diseases, diabetes, psoriasis, skin aging, and skin issues in different levels. We aim to further develop our Lactoactive^® molecule for the purpose of increasing the quality of our retail and medical skin cream products as well as licensing out our Lactoactive^® molecule for the pharmaceutical industry.

Vilacto Bio Inc.
Fabriksvej 48
4700 Naestved
Denmark

Gert Andersen
Phone: +1 646-893-7895
[email protected]
www.vilactobio.com

Forward-Looking Statements & Disclaimers:

The information in this Press Release includes certain "forward-looking" statements within the meaning of the Safe Harbor provisions of Federal Securities Laws, as that term is defined in section 27a of the United States Securities Act of 1933, as amended, and section 21e of the United States Securities Exchange Act of 1934, as amended. Statements in this document, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Investors are cautioned that such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release, and the Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.